Resumen

Diarrhoea is an important cause of morbidity and mortality in all regions of the world and among all ages. It has been estimated that 91 million individuals worldwide contract shigellosis each year and among them 1.1 million die. About, 410,000 (40%) of these deaths occur among Asian children. Appropriate antibiotic treatment of shigellosis depends on identifying resistance patterns. Rapid emergence of resistance warrants the need for continuous monitoring of sensitivity patterns. The emergence of multiple-drug resistant (MDR) strains of Shigella sp., especially over the last two decades, has made the treatment for shigellosis more difficult. Currently ciprofloxacin (or other fluoroquinolones) is recommended as the drug of choice by the World Health Organization for the therapy of Shigella infections in both adults and children.

Palabras clave: Shigella S. sonnei 3^rd generation cephalosporin resistance.

2011-10-05   |   582 visitas   |   Evalua este artículo 0 valoraciones

Vol. 5 Núm.9. Septiembre 2011 Pags. 674-676 J Infect Developing Countries 2011; 5(9)